United Therapeutics announces FDA clearance to proceed with Summit clinical trial for treprostinil SMI in PH-COPD
UTHR•United Therapeutics received FDA clearance to proceed with its Summit clinical trial of treprostinil SMI in PH-COPD and anticipates a Phase 3 study in 2028.
1. Trial clearance
United Therapeutics Corporation said it received FDA clearance to proceed with the Summit clinical trial for treprostinil SMI in PH-COPD. The company anticipates a Phase 3 study in 2028.
